Teamwork Financial Advisors LLC Sells 7,378 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Teamwork Financial Advisors LLC trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 73.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,717 shares of the pharmaceutical company’s stock after selling 7,378 shares during the period. Teamwork Financial Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,094,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of VRTX. Edgewood Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 7,876.3% during the third quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company’s stock worth $719,186,000 after buying an additional 1,526,983 shares in the last quarter. Jennison Associates LLC increased its stake in Vertex Pharmaceuticals by 18.1% in the 3rd quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock valued at $2,581,373,000 after buying an additional 851,054 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Vertex Pharmaceuticals by 17.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock worth $2,231,858,000 after buying an additional 704,421 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Vertex Pharmaceuticals by 169.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 839,672 shares of the pharmaceutical company’s stock valued at $338,136,000 after acquiring an additional 528,029 shares during the last quarter. Finally, International Assets Investment Management LLC raised its holdings in Vertex Pharmaceuticals by 74,015.5% during the third quarter. International Assets Investment Management LLC now owns 324,626 shares of the pharmaceutical company’s stock worth $150,977,000 after acquiring an additional 324,188 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $428.00 on Thursday. The firm has a 50-day moving average of $436.77 and a 200-day moving average of $465.13. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm has a market cap of $110.22 billion, a P/E ratio of -215.08, a P/E/G ratio of 2.20 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the prior year, the firm posted $3.67 earnings per share. The business’s revenue was up 11.6% on a year-over-year basis. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Wells Fargo & Company decreased their target price on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Morgan Stanley increased their price target on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. HC Wainwright decreased their price objective on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a report on Friday, December 20th. Finally, Stifel Nicolaus raised their target price on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research note on Monday, December 16th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $490.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.